Two groups look to bring standardization to cell therapy manufacturing in their latest paper
As cell therapies are becoming used more and more in medicine, two groups are looking to standardize cell therapy manufacturing so it can eventually become more widely available.
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing BioPharmaceuticals (NIIMBL) have released a paper called Project A-Cell, a collaboration meant to analyze how to incorporate Quality by Design (QbD) principles specifically in the manufacturing of CAR-T cell therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.